Catalyst Wire Dossier Catalyst Wire Dossier

Dolutegravir + Emtricitabine/Tenofovir Alafenamide

dolutegravir · Gilead Sciences
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Dolutegravir + Emtricitabine/Tenofovir Alafenamide, covering 2018-03-27 to 2018-06-06. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults [Phase 3]

See pricing